NASDAQ: TWSTTwist Bioscience Corp Stock
$47.28+2.27 (+5.04%)
Updated Mar 17, 2026
TWST Price
$47.28
Fair Value Price
$11.48
Market Cap
$2.90B
52 Week Low
$23.30
52 Week High
$57.88
P/E
-37.23x
P/B
6.36x
P/S
4.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$391.56M
Earnings
-$76.58M
Gross Margin
51.6%
Operating Margin
-19.3%
Profit Margin
-19.6%
Debt to Equity
0.4
Operating Cash Flow
-$51M
Beta
2.34
Next Earnings
Apr 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TWST Overview
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TWST's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
TWST
Ranked#30 of 43
Ranked#30 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $120.84 | A | |
| $13.85 | A | |
| $69.76 | B |
Be the first to know about important TWST news, forecast changes, insider trades & much more!
TWST News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TWST scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TWST ($47.28) is overvalued by 311.77% relative to our estimate of its Fair Value price of $11.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TWST ($47.28) is not significantly undervalued (311.77%) relative to our estimate of its Fair Value price of $11.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TWST due diligence checks available for Premium users.
Valuation
TWST fair value
Fair Value of TWST stock based on Discounted Cash Flow (DCF)
Price
$47.28
Fair Value
$11.48
Overvalued by
311.77%
TWST ($47.28) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TWST ($47.28) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TWST is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TWST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-37.23x
Industry
16.59x
Market
32.45x
TWST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.36x
Industry
3.68x
TWST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TWST's financial health
Profit margin
Revenue
$103.7M
Net Income
-$30.5M
Profit Margin
-29.4%
TWST's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TWST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$638.1M
Liabilities
$182.0M
Debt to equity
0.4
TWST's short-term assets ($303.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TWST's short-term assets ($303.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TWST's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TWST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.8M
Investing
-$9.9M
Financing
$298.0k
TWST's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TWST vs Diagnostic & Research Stocks
Twist Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.